Abstract | BACKGROUND: METHODS: We performed a combined analysis of individual patient data from two clinical trials (COLCOT, LoDoCo-MI). Paired pre-treatment and post-treatment hs-CRP (mg/L) were available in 222 patients for LoDoCo-MI and 207 patients for COLCOT (npooled = 429). We evaluated the effect of colchicine vs. placebo on post-treatment hs-CRP coded continuously and ≤ 1.0 mg/L in adjusted mixed-model multi-level regression analyses. RESULTS:
Colchicine was not significantly associated with post-treatment hs-CRP when it was considered as a continuous variable (beta: -0.41, P = 0.429). However, the intervention was significantly associated with increased odds of achieving post-treatment hs-CRP values ≤1.0 mg/L compared to placebo (odds ratio: 1.64, 95% confidence interval: 1.07 to 2.51, P = 0.024). CONCLUSIONS: Reduction of inflammation may be a key component in the clinical efficacy of low-dose colchicine with respect to decreased risk of recurrent cardiovascular events following MI. Systematic sampling of hs-CRP before and after treatment with colchicine may be relevant.
|
Authors | Maxine Sun, Marie-Pierre Dubé, Thomas Hennessy, Carl J Schultz, Amina Barhdadi, David Rhainds, Graham S Hillis, Jean-Claude Tardif |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 363
Pg. 20-22
(09 15 2022)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 35716932
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2022 Elsevier B.V. All rights reserved. |
Chemical References |
- Biomarkers
- C-Reactive Protein
- Colchicine
|
Topics |
- Biomarkers
- C-Reactive Protein
(metabolism)
- Colchicine
(therapeutic use)
- Humans
- Inflammation
(drug therapy)
- Myocardial Infarction
(therapy)
|